Affiliation:
1. National Blood Service, Cambridge Blood Centre
2. Refik Saydam Hygiene Centre, Department of Virology, Ankara, Turkey
3. Division of Transfusion Medicine, Department of Haematology, University of Cambridge, Cambridge, United Kingdom
Abstract
ABSTRACT
The presence of human erythrovirus DNA in 2,440 blood donations from the United Kingdom and sub-Saharan Africa (Ghana, Malawi, and South Africa) was screened. Sensitive qualitative and real-time quantitative PCR assays revealed a higher prevalence of persistent infection with the simultaneous presence of immunoglobulin G (IgG) and viral DNA (0.55 to 1.3%) than previously reported. This condition was characterized by a low viral load (median, 558 IU/ml; range, 42 to 135,000 IU/ml), antibody-complexed virus, free specific IgG, and potentially infectious free virus. Human erythrovirus genotype 1 (formerly parvovirus B19) was prevalent in the United Kingdom, Malawi, and South Africa. In contrast, only human erythrovirus genotype 3 (erythrovirus variant V9) was prevalent in Ghana. Genotype 3 had considerable genetic diversity, clustering in two probable subtypes. Genotype 1-based antibody assays failed to detect 38.5% of Ghanaian samples containing antibodies to genotype 3 virus but did not fail to detect cases of persistent infection. This study indicates a potential African origin of genotype 3 human erythrovirus and considerable shortcomings in the tools currently used to diagnose erythrovirus infection.
Publisher
American Society for Microbiology
Subject
Virology,Insect Science,Immunology,Microbiology
Reference43 articles.
1. Allain, J.-P., D. Candotti, K. Soldan, F. Sarkodie, B. Phelps, C. Giachetti, V. Shyamala, F. Yeboah, M. Anokwa, S. Owusu-Ofori, and O. Opare-Sem. 2003. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood101:2419-2425.
2. Aubin, J.-T., C. Defer, M. Vidaud, M. Maniez Montreuil, and B. Flan. 2000. Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang.78:7-12.
3. Blumel, J., I. Schmidt, W. Effenberger, H. Seitz, H. Willkommen, H. H. Brackmann, J. Lower, and A. M. Eis-Hubinger. 2002. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion42:1473-1481.
4. Brechot, C., V. Thiers, D. Kremsdorf, B. Nalpas, S. Pol, and P. Paterlini-Brechot. 2001. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology34:194-203.
5. Brown, K. E., N. S. Young, B. M. Alving, and L. H. Barbosa. 2001. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion41:130-135.
Cited by
155 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献